Focusing on Hepatitis B, New Developments in the “Oasis” Project and Exploration of TAF’s Immune Modulation Effects

Focusing on Hepatitis B, New Developments in the “Oasis” Project and Exploration of TAF’s Immune Modulation Effects

The annual highlight in the field of hepatology, the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, is currently taking place in Boston, USA. Two research achievements related to the treatment and management of hepatitis B by Dr. Wenhong Zhang and Dr. Jiming Zhang 's team from Huashan Hospital, affiliated with Fudan University, have been included in the conference. One is a phase analysis of the Oasis Project, a study aimed at reducing the occurrence of liver cancer in Chinese hepatitis B patients, revealing the safety and benefits of interferon application in specific populations. The other explores the immune modulation effects of tenofovir alafenamide (TAF) treatment and predictive indicators of efficacy. "Hepatology Digest" hereby reports on these findings.
Presentation of Research Achievements in Liver Transplantation and New Insights into Liver Transplantation Progress

Presentation of Research Achievements in Liver Transplantation and New Insights into Liver Transplantation Progress

From November 10th to 14th, 2023, the annual grand event in the field of hepatology, the American Association for the Study of Liver Diseases Annual Meeting (AASLD2023), took place in Boston, USA. The on-site reporting team of "Hepatology Digest" had the privilege of inviting Dr. Wei Rao's team from the Organ Transplant Center of Qingdao University Affiliated Hospital, to introduce the team's achievements, share their experiences at the conference, and discuss future research directions. The interview content is shared below.
AASLD Voice of China | Dr. Liang Peng’s Team: Release of Clinical and Basic Research Results on Multiple Hepatitis B Studies, Preliminary Confirmation

AASLD Voice of China | Dr. Liang Peng’s Team: Release of Clinical and Basic Research Results on Multiple Hepatitis B Studies, Preliminary Confirmation

From November 10th to 14th, 2023, the annual international highlight event in the field of hepatology, the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, is being held in Boston, USA. Dr. Liang Peng's team from the Third Affiliated Hospital of Sun Yat-sen University has had multiple research results included in the conference. One randomized controlled trial evaluated the safety and effectiveness of tenofovir alafenamide fumarate (TAF) treatment for hepatitis B "healthy" carriers, and preliminary results indicate that TAF is safe for this population, with a rapid decrease in HBV DNA after 24 weeks of antiviral therapy, especially in the HBeAg-negative group where the HBV DNA undetectable rate is high [1].
Dr. Qin Ning’s Team: Focus on Hepatitis B, Fatty Liver, Liver Injury, and End-Stage Liver Disease, Unveiling 8 Achievements at the AASLD Meeting

Dr. Qin Ning’s Team: Focus on Hepatitis B, Fatty Liver, Liver Injury, and End-Stage Liver Disease, Unveiling 8 Achievements at the AASLD Meeting

From November 10th to 14th, 2023, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2023) was grandly held in Boston, USA. Dr. Qin Ning's team from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, presented 2 posters of distinction and 6 posters on scientific research in the fields of liver injury, fatty liver, hepatitis B, end-stage liver disease, and complications. "Hepatology Digest" hereby reports on some of the research abstracts, providing you with a glimpse of the team's achievements.
Dr. Xuefeng Luo’s Team: Poor Prognosis for Acute Variceal Bleeding with Liver Cancer, Liver Function Grading and Tumor Staging as Major Risk Factors

Dr. Xuefeng Luo’s Team: Poor Prognosis for Acute Variceal Bleeding with Liver Cancer, Liver Function Grading and Tumor Staging as Major Risk Factors

From November 10th to 14th, 2023, the annual highlight of the liver disease field, the American Association for the Study of Liver Diseases (AASLD) Annual Meeting 2023, was grandly held in Boston, USA. Several research achievements from Dr. Xuefeng Luo's team at West China Hospital of Sichuan University were included in the conference [1-3], with one poster earning the distinction of "Poster of Distinction." International Liver Disease hereby reports on the team's latest findings exploring the clinical outcomes and prognostic factors in patients with acute variceal bleeding (AVB) combined with liver cell carcinoma (HCC) and liver cirrhosis, providing valuable insights for readers.
Breakthrough in Clinical Treatment of Chronic Drug-Induced Liver Injury: Optimizing Steroid Regimen and Indications – A Voice from AASLD China

Breakthrough in Clinical Treatment of Chronic Drug-Induced Liver Injury: Optimizing Steroid Regimen and Indications – A Voice from AASLD China

Recently, the Liver Disease Department and Pathology Department at the Fifth Medical Center of the People's Liberation Army General Hospital (formerly the PLA Third O2 Hospital) collaborated to achieve a new breakthrough in the clinical treatment of Chronic Drug-Induced Liver Injury (DILI). The research teams, led by Dr. Zhengsheng Zou, Jingmin Zhao, and Dong Ji, previously pioneered the establishment of a 48-week Steroid Stepwise Reduction (48w-SSR) treatment plan for chronic recurrent DILI, demonstrating its efficacy and safety through rigorous Randomized Controlled Trials (RCTs). The results were published in the prestigious journal Alimentary Pharmacology & Therapeutics (a TOP journal in the 1st area of the Chinese Academy of Sciences).
Doctor Thomas Reiberger: Hotly Debated Issues on the Use of Non-Selective Beta-Blockers (NSBBs) in the Treatment of Cirrhosis

Doctor Thomas Reiberger: Hotly Debated Issues on the Use of Non-Selective Beta-Blockers (NSBBs) in the Treatment of Cirrhosis

🔍 Exploring the Complexities of Cirrhosis Treatment: Insights from Dr. Thomas Reiberger Welcome to the latest feature from Hepatology Digest, where we delve into the nuanced world of liver health. In our upcoming article, we're excited to present the esteemed Dr. Thomas Reiberger, a leading figure in hepatology, known for his extensive research and clinical expertise. Dr. Reiberger brings a wealth of knowledge to the table, particularly in the controversial use of Non-Selective Beta-Blockers (NSBBs) for treating cirrhosis. Join us as we navigate the complexities of this treatment, examining its benefits, challenges, and the heated debates it sparks in the medical community. Stay tuned for an enlightening journey through the lens of a distinguished expert. 🔗 Stay connected with Hepatology Digest for cutting-edge insights and discussions.
Dr. Lai Wei’s Team at Tsinghua Chang Gung: Latest Developments in the Nationwide “MAFLD Epidemiological Survey Research Project” on Health Check-up

Dr. Lai Wei’s Team at Tsinghua Chang Gung: Latest Developments in the Nationwide “MAFLD Epidemiological Survey Research Project” on Health Check-up

In 2020, the international expert consensus on metabolic dysfunction-associated fatty liver disease (MAFLD) proposed a new definition, suggesting MAFLD as a more appropriate term to describe liver diseases related to metabolic dysfunction. According to the latest standards, patients with liver fat deposition meet at least one of the following three criteria: overweight or obesity, type 2 diabetes, or the presence of metabolic dysfunction (if their weight is normal). To comprehensively understand the current status of MAFLD in China, promote awareness among medical professionals and patients, and increase the diagnosis rate of the disease, in 2022, the National Health Examination Population "MAFLD Epidemiological Survey Research Project," led by Dr. Lai Wei of Tsinghua University Affiliated Beijing Tsinghua Chang Gung Hospital and co-initiated by the China Liver Health Promotion Center, was successfully launched. The two latest research findings from the project have been included in the 2023 Annual Meeting of the American Association for the Study of Liver Disease (AASLD). Dr. Lai Wei has been invited by the Hepatology Digest to provide a detailed introduction to these two studies, the content of which is shared below.